Strong pairing at iron 3dxz,yz3d_{xz,yz} orbitals in hole-doped BaFe2_2As2_2

Among numerous hypotheses, recently proposed to explain superconductivity in iron-based superconductors [1-9], many consider Fermi surface (FS) nesting [2, 4, 8, 10] and dimensionality [4, 9] as important contributors. Precise determination of the electronic spectrum and its modification by superconductivity, crucial for further theoretical advance, were hindered by a rich structure of the FS [11-17]. Here, using the angle-resolved photoemission spectroscopy (ARPES) with resolution of all three components of electron momentum and electronic states symmetry, we disentangle the electronic structure of hole-doped BaFe2As2, and show that nesting and dimensionality of FS sheets have no immediate relation to the superconducting pairing. Alternatively a clear correlation between the orbital character of the electronic states and their propensity to superconductivity is observed: the magnitude of the superconducting gap maximizes at 10.5 meV exclusively for iron 3dxz;yz orbitals, while for others drops to 3.5 meV. Presented results reveal similarities of electronic response to superconducting and magneto-structural transitions [18, 19], implying that relation between these two phases is more intimate than just competition for FS, and demonstrate importance of orbital physics in iron superconductors.Comment: read m

Marketing e empreendedorismo: uma relação umbilical

Este relatório, ao constatar a diferente aplicabilidade dos conhecimentos e utensílios de marketing, devido às empresas maduras e de maior dimensão desfrutarem de recursos que os empreendedores e gestores de pequenas empresas não possuem, tem como objetivo, baseado na experiencia profissional do autor e respetivo enquadramento teórico e científico, caracterizar a relação entre o marketing e o empreendedorismo, permitindo uma melhor compreensão das alternativas existentes para os empreendedores e gestores de pequenas empresas, além de uma identificação dos seus comportamentos e atitudes mais recorrentes. Neste contexto, ganha preponderância uma reflexão sobre o marketing empreendedor, como ocorre e em que circunstâncias pode auxiliar o empreendedor a tomar decisões e simultaneamente não perder competitividade para os seus potenciais concorrentes. Assim, a comunicação boca-a-boca, o círculo de influências do empreendedor e as redes sociais inovadoras, são cada vez mais consideradas e reconhecidas como garante de competitividade e inovação, num ambiente empresarial em constante mudança; ABSTRACT: This report, observes the different applicability of the knowledge and marketing tools, justified by the existence of bigger possessions that mature companies have, comparing to the resources that the entrepreneurs and managers of small companies do not own. This report, based in the professional experience of the author and theoretical and scientific knowledge, aims to characterize the connection between marketing and the entrepreneurship, allowing a better understanding of the alternatives and behaviors that entrepreneurs and managers of small companies could take, in order to compete with their rivals. In this context, it gains prominence a reflection on the entrepreneurial marketing, when it occurs and which circumstances can assist the entrepreneur to take decisions in order to not lose competitiveness for its potential opponents. Thus, the buzz communication, the circle of influences of the entrepreneur and the new social networks, are each time more considered and recognized as it guarantees of competitiveness and innovation, in an enterprise environment constantly in change

Acute childhood diarrhoea in northern Ghana: epidemiological, clinical and microbiological characteristics

<p>Abstract</p> <p>Background</p> <p>Acute diarrhoea is a major cause of childhood morbidity and mortality in sub-Saharan Africa. Its microbiological causes and clinico-epidemiological aspects were examined during the dry season 2005/6 in Tamale, urban northern Ghana.</p> <p>Methods</p> <p>Stool specimens of 243 children with acute diarrhoea and of 124 control children were collected. Patients were clinically examined, and malaria and anaemia were assessed. Rota-, astro-, noro- and adenoviruses were identified by (RT-) PCR assays. Intestinal parasites were diagnosed by microscopy, stool antigen assays and PCR, and bacteria by culturing methods.</p> <p>Results</p> <p>Watery stools, fever, weakness, and sunken eyes were the most common symptoms in patients (mean age, 10 months). Malaria occurred in 15% and anaemia in 91%; underweight (22%) and wasting (19%) were frequent. Intestinal micro-organisms were isolated from 77% of patients and 53% of controls (<it>P </it>< 0.0001). The most common pathogens in patients were rotavirus (55%), adenovirus (28%) and norovirus (10%); intestinal parasites (5%) and bacteria (5%) were rare. Rotavirus was the only pathogen found significantly more frequently in patients than in controls (odds ratio 7.7; 95%CI, 4.2–14.2), and was associated with young age, fever and watery stools. Patients without an identified cause of diarrhoea more frequently had symptomatic malaria (25%) than those with diagnosed intestinal pathogens (12%, <it>P </it>= 0.02).</p> <p>Conclusion</p> <p>Rotavirus-infection is the predominant cause of acute childhood diarrhoea in urban northern Ghana. The abundance of putative enteropathogens among controls may indicate prolonged excretion or limited pathogenicity. In this population with a high burden of diarrhoeal and other diseases, sanitation, health education, and rotavirus-vaccination can be expected to have substantial impact on childhood morbidity.</p

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Integrated chitinozoan, conodont, and graptolite biostratigraphy from the upper part of the Cape Cormorant Formation (Middle Ordovician), western Newfoundland

The Cape Cormorant Formation of the Table Head Group exposed on the Port au Port Peninsula, western Newfoundland, is composed of dark-brown to black shales with interbeds of thin calcareous silty and sandy distal turbidites. Distinctive carbonate conglomerates and breccias derived from the foundering shelf are occasionally found in the formation. The sediments accumulated in the foreland basin formed during the early stage of the Taconic orogeny. The faunas from the upper part of the Cape Cormorant Formation include graptolites, conodonts, and chitinozoans. The graptolites are well preserved, but are of low diversity and are referred to the Darriwil Pterograptus elegans Zone. Conodonts recorded from the distal turbidites are rare and fragmented. The faunas include taxa that are known from the St. George and Table Head groups. The conodont fauna is tentatively assigned to the Histiodella kristinae Phylozone and to the younger, unzoned interval. The chitinozoans are well preserved and the yield is high. The fauna is assigned to the Cyathochitina jenkinsi Zone and to an undefined interval. The abundance and diversity of the chitinozoan assemblages display a cyclic pattern, which is related to changes of the oceanic watermass in the foreland basin. The new chitinozoan species Belonechitina nevillensis n. sp., Belonechitina uniformipunctata n. sp., and Cyathochitina cormorani n. sp. are described